Skip to main content

Table 2 Efficacy and safety profiles of modelled interventions

From: Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece

  Metformina Meformin + glimepiridea Metformin + vildagliptina Metformin + basal insulinb Metformin + intensive insulinb
HbA1c initial absolute 1 year change −1.03 −0.53 −0.44 −1.10 −1.10
Symptomatic Hypoglycaemia Risk (per year), % 0.00 16.20 1.66 16.20 16.20
Severe Hypoglycaemia Risk (per year), % 0.00 1.38 0.00 3.30 3.30
Weight gain (kg/year) 0.00 1.56 -0.23 1.70 1.70
  1. aSource: Ferrannini et al. [15]
  2. bSource: Monami et al. [21]